Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Ibrutinib + Venetoclax |
| Indication/Tumor Type | diffuse large B-cell lymphoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | diffuse large B-cell lymphoma | sensitive | Ibrutinib + Venetoclax | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK C481S resulting in Imbruvica (ibrutinib) resistance demonstrated increased sensitivity to Imbruvica (ibrutinib) when also treated with Venclexta (venetoclax), demonstrating decreased cell growth in culture (PMID: 28428442). | 28428442 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28428442) | Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. | Full reference... |